I wonder if it worth considering that a lot of big companies (including U.S. companies) might have a lot to lose if MSB's stem cell treatment gets properly validated in a trial and approved by the FDA. Stem cells have a possible use in a many inflammatory indications..
I remember reading that the person who voted against MSB at the ODAC meeting for GVHD treatment Remestemcel had a conflict of interest as he worked for another stem cell company..
Interesting reading here..
https://seekingalpha.com/article/4396080-mesoblast-future-looks-bleak
I wonder if it worth considering that a lot of big companies...
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.020(2.08%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | 99.5¢ | 97.0¢ | $1.219M | 1.243M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 106373 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 34261 | 19 |
View Market Depth
| Last trade - 12.16pm 22/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |